MESO has a diversified portfolio targeting inflammatory conditions, majorly led by products Remestemcel-L and Rexlemestrocel-L. The recent FDA rejection of Remestemcel-L poses a challenge, but ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In a recent update, NovoCure Ltd.
Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results